Changchun High-Tech Industry Group Co Ltd: Financial Highlights and Market Activity
Changchun High-Tech Industry Group Co Ltd, an investment holding company listed on the Shenzhen Stock Exchange, is primarily engaged in the manufacturing of biopharmaceuticals and Chinese traditional medicines. The company also constructs infrastructure facilities, manufactures electrolytic condensers, and develops and manages real estate. As of August 31, 2025, the company’s close price was 113.37 CNH, with a 52-week high of 125.78 CNH on October 8, 2024, and a 52-week low of 77.5 CNH on September 9, 2024. The market capitalization stood at 41.74 billion CNH, with a price-to-earnings ratio of 20.89.
Recent Market Activity
On September 2, 2025, Changchun High-Tech Industry Group Co Ltd, trading under the ticker 000661, experienced significant market activity. The company’s stock price surged by 10.00%, closing at 124.71 CNH. This performance was part of a broader trend where the stock was favored by brokerage departments, with net purchases exceeding 10% of the day’s trading volume.
Net Purchases and Market Interest: The company was among the top net purchased stocks, with brokerage departments net buying 27,943.89 thousand CNH, accounting for 10.22% of the day’s trading volume. This interest was part of a larger trend where 21 stocks were net purchased, while 23 were net sold by brokerage departments.
Institutional Interest: The stock also appeared on the Shenzhen-Hong Kong Stock Connect (深股通) list, indicating institutional interest. The stock was net sold by the Stock Connect by 450.96 thousand CNH, despite its strong performance.
Market Volatility: The stock’s price movement led to its inclusion on the volatility list, with a cumulative price deviation exceeding 20% over two consecutive trading days. This triggered a public announcement regarding the stock’s volatility.
Industry Context
The company’s performance is part of a broader trend in the pharmaceutical sector, where innovation in drug development is gaining momentum. The biopharmaceutical industry, in particular, has seen increased attention due to advancements in AI-driven drug design and the global recognition of Chinese pharmaceutical innovations.
Conclusion
Changchun High-Tech Industry Group Co Ltd’s recent market performance highlights its strong position within the pharmaceutical sector and the broader market’s interest in its growth potential. The company’s strategic focus on biopharmaceuticals and traditional medicines, coupled with its diversified business operations, positions it well for continued growth in the evolving healthcare landscape.